TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus

Abstract Erosive oral lichen planus (OLP) is a challenging disease. This T cell driven disorder frequently shows a treatment unresponsive course and strongly limits patients' quality of life. The disease lacks FDA or EMA approved drugs for its treatment and the efficacy of the commonly administered treatments (i.e. topical and systemic steroids, steroid sparing agents) is often only partial. Although the etiopathogenesis of the disease still needs to be fully elucidated, recent advances helped to identify interferon‐ɣ (IFN‐ɣ) as a pivotal cytokine in OLP pathogenesis, thus making the interference with its signalling a therapeutic target. Janus kinase (JAK) inhibitors therefore gained relevance for their inhibitory effect on IFN‐ɣ signalling. While some drugs such as abrocitinib, upadacitinib, tofacitinib directly interfere with IFN‐ɣ signalling through blockade of JAK1 and/or JAK2, deucravacitinib, a selective TYK‐2 inhibitor indirectly interferes on IFN‐ɣ activation through interference with interleukin (IL)‐12, a potent promotor for Th1/IFN‐ɣ responses. This mechanism of action makes deucravacitinib a candidate drug for the treatment of OLP. Here we provide initial evidence that deucravacitinib 6 mg daily has a beneficial effect in three patients with oral OLP.